A Phase 3 interventional study of Gantenerumab and Placebo in Alzheimer Disease, sponsored by Hoffmann-La Roche. Terminated at 172 sites in 15 countries. Open to participants aged 50 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-01-30.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing gantenerumab in Alzheimer Disease — none open to participants now, 1 under way, 1 of them phase 3. gantenerumab · Alzheimer Disease.
Among the 13 studies testing gantenerumab in Alzheimer Disease, this one is the 2nd largest by enrollment, is one of 2 that started in 2018, is one of 7 in phase 3, and was the 6th registered.
3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.
Browse Alzheimer Disease studies →None of the 13 studies testing gantenerumab in Alzheimer Disease is open now. The open studies under Alzheimer Disease, anywhere →
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 643 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 285 take healthy volunteers.
This study: 50 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 10
First in 2006; this study’s year is marked. 2 started in 2018.
This study's enrollment of 1,053 is above the median of 70 across 3,024 interventional studies indexed under Alzheimer Disease.
Median enrollment 194 across the 13 interventional studies. Of the 12 that completed or were terminated, 10 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
10 of 13 have an industry lead sponsor. The 3 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 331 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
40 studies in Alzheimer Disease by Hoffmann-La Roche: 3 open now, 8 under way, 4 of them phase 3. Of 32 finished, 18 (56%) have results posted.
Among the 40 studies in Alzheimer Disease by Hoffmann-La Roche, this one is the 6th largest by enrollment, is one of 3 that started in 2018, is one of 14 in phase 3, and was the 21st registered.
Hoffmann-La Roche’s Alzheimer Disease studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing gantenerumab in Alzheimer Disease, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 40 in Alzheimer Disease:
This tab as a report to print or save as PDF → With an account.
This randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of gantenerumab versus placebo in participants with early (prodromal to mild) AD. All participants must show evidence of beta-amyloid pathology. Eligible participants will be randomized 1:1 to receive either subcutaneous (SC) injection of gantenerumab or placebo. The primary efficacy assessment will be performed at the end of the double blind period at week 116. Participants will then be offered to enter into an open-label extension (OLE). Participants not willing to go to the OLE will participate in a long term follow-up period for up to 50 weeks after the last gantenerumab dose.
Key Inclusion criteria:
Key Exclusion criteria:
Exclusion for Open-Label Extension (OLE):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Gantenerumab will be administered as SC injections with gradual uptitration.
Drug: Gantenerumab
Placebo will be administered as SC injections with gradual uptitration.
Drug: Placebo
Gantenerumab will be administered as per the schedule specified in the respective arm.
Also known as: RO4909832
Placebo will be administered as per the schedule specified in the respective arm.
DBT Period: Change From Baseline to Week 116 in Global Outcome, as Measured by CDR-SB
CDR was derived through semi-structured interview with the participant and an appropriate informant, and it rated impairment across six domains: memory, orientation, judgment, and problem solving, community affairs, home and hobbies, and personal care on a 5-point scale for which 0=no impairment, 0.5=questionable impairment, and 1, 2, and 3=mild, moderate, and severe impairment, respectively. The CDR-SB is based on summing each of the domain box scores with total score ranging from 0-18 with higher scores reflecting greater cognitive and functional impairment. A negative change from baseline indicates improvement.
Time frame: Baseline, Week 116
China Extension: DBT Period: Change From Baseline to Week 116 in Global Outcome, as Measured by CDR-SB
CDR was derived through semi-structured interview with the participant and an appropriate informant, and it rated impairment across six domains: memory, orientation, judgment, and problem solving, community affairs, home and hobbies, and personal care on a 5-point scale for which 0=no impairment, 0.5=questionable impairment, and 1, 2, and 3=mild, moderate, and severe impairment, respectively. The CDR-SB is based on summing each of the domain box scores with total score ranging from 0-18 with higher scores reflecting greater cognitive and functional impairment. A negative change from baseline indicates improvement.
Time frame: Baseline, Week 116
DBT Period: Change From Baseline to Week 116 in Alzheimer Disease Assessment Scale-Cognition Subscale 13 (ADAS-Cog13) Score
The ADAS-Cog13 total score includes all of the items in the ADAS-Cog11 in addition to delayed word recall and the number cancellation. For the ADAS-cog 13 the range is 0-85 (score range for Delayed Word Recall \[DWR\] score is 0-10 and for Number Cancellation \[NC\] is 0-5, thus the score is ADAS-cog 11\[0-70\] plus the scores for DWR and NC). A higher score indicates worse performance. A negative change from baseline indicates improvement in cognitive function.
Time frame: Baseline, Week 116
DBT Period: Change From Baseline to Week 116 in Alzheimer's Disease Cooperative Study- Activities of Daily Living (ADCS-ADL) Total Score
ADCS-ADL is a 23-item rater-administered, observer-reported outcome (ObsRO) that captures a participant's ability to perform basic activities of daily living (e.g., eating and toileting) and more complex ADL or instrumental activities of daily living (iADL, e.g., using the telephone, managing finances, preparing a meal). Total score ranges from 0-78, with higher scores reflecting better functioning. A positive change from baseline indicates improvement.
Time frame: Baseline, Week 116
DBT Period: Change From Baseline to Week 116 in Functional Activities Questionnaire (FAQ) Score
FAQ is a rater-administered ObsRO (informant-based measure) that measures a participant's functional ability to perform complex higher-order activities. The observer provides performance ratings of the target person on ten complex higher-order activities. Total score that ranges from 0-30, with higher scores reflecting greater functional impairment. A negative change from baseline indicates improvement.
Time frame: Baseline, Week 116
DBT Period: Change From Baseline to Week 116 in Mini-Mental State Examination (MMSE) Total Score
MMSE is a rater-administered performance-based outcome (PerfO) that includes a set of standardized questions used to evaluate possible cognitive impairment and help stage the severity level of this impairment. The questions target six areas: orientation, registration, attention, short-term recall, language, and constructional praxis/visuospatial abilities. Total score ranges from 0-30, with lower scores indicating greater impairment. A positive change from baseline indicates improvement.
Time frame: Baseline, Week 116
DBT Period: Change From Baseline to Week 116 in Alzheimer Disease Assessment Scale-Cognition Subscale 11 (ADAS-Cog11) Score
The ADAS-Cog11 was designed to measure cognitive symptom change in participants with Alzheimer's Disease (AD) and consisted of 11 tasks. The standard 11 items (and corresponding score range) were: word recall (0-10), commands (0-5), constructional praxis (0-5), naming objects and fingers (0-5), ideational praxis (0-5), orientation (0-8), word recognition (0-12), spoken language ability (0-5), comprehension of spoken language (0-5), word-finding difficulty (0-5), and remembering test instructions (0-5). The test included 7 performance items and 4 clinician-rated items. The ADAS-Cog11 total score was the sum of all 11 individual items, with a total score ranging from 0 (no impairment) to 70 (severe impairment). Higher scores indicated more severe cognitive impairment. A negative change from baseline indicates improvement.
Time frame: Baseline, Week 116
DBT Period: Change From Baseline to Week 116 in Verbal Fluency Task (VFT) Score
VFT is a rater administered PerfO that measures speed and flexibility of verbal thought with a total score that ranges from 0-99 (lower scores indicating lower performance). A positive change from baseline indicates improvement.
Time frame: Baseline, Week 116
DBT Period: Change From Baseline to Week 116 in the Coding (Digit Symbol Substitution Test [DSST]) Subtest
Coding, also called DSST is a rater administered PerfO that measures speed of processing and associative memory with a total score that ranges from 0-135 (lower scores indicating lower performance). The DSST was adapted from the Wechsler Adult Intelligence Scale. The 120-second version of the test was used in this study. Positive change from baseline indicates improvement.
Time frame: Baseline, Week 116
DBT Period: Change From Baseline to Week 116 in Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-iADL) Instrumental Score
The ADCS-iADL measures activities such as using the telephone, shopping and preparing a meal. The ADCS-iADL consists of 16 questions with a score range of 0 to 56 where a higher score represents better function. Positive change from baseline indicates improvement.
Time frame: Baseline, Week 116
DBT Period: Number of Participants With at Least One Adverse Event (AE)
An AE is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution.
Time frame: From Day 1 up to 14 weeks after the last dose of blinded study drug (up to 131 weeks)
DBT Period: Number of Participants With Post-baseline Suicidal Ideation or Suicidal Behavior as Measured Using Columbia-Suicide Severity Rating Scale (C-SSRS)
C-SSRS=assessment tool used to assess lifetime suicidality of a participant (at baseline) as well as any new instances of suicidality (C-SSRS since last visit). Structured interview prompts recollection of suicidal ideation, including intensity of ideation, behavior, \& attempts with actual/potential lethality. Categories have binary responses (yes/no) \& include Wish to be Dead; Non-specific Active Suicidal Thoughts; Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; Active Suicidal Ideation with Some Intent to Act, without Specific Plan; Active Suicidal Ideation with Specific Plan and Intent, Preparatory Acts and Behavior; Aborted Attempt; Interrupted Attempt; Actual Attempt (non-fatal); Completed Suicide. Suicidal ideation/behavior is indicated by a "yes" answer to any of the listed categories. Score of 0 is assigned if no suicide risk is present. Score of 1 or higher= suicidal ideation or behavior. Categories with non-zero values are only reported here.
Time frame: From Day 1 up to 14 weeks after the last dose of blinded study drug (up to 131 weeks)
DBT Period: Number of Participants With at Least One Amyloid-Related Imaging Abnormalities-Edema (ARIA-E) Magnetic Resonance Imaging (MRI) Finding
ARIA are an identified risk with anti-amyloid antibodies, including gantenerumab. These changes can be identified on brain MRI. In ARIA-E, (E for oedema or effusion), oedema can be seen in different areas of the brain on MRI, representing fluid leakage into the brain parenchyma or sulcal spaces.
Time frame: From Day 1 up to 14 weeks after the last dose of blinded study drug (up to 131 weeks)
DBT Period: Number of Participants With at Least One Amyloid-Related Imaging Abnormalities-Haemosiderin Deposition (ARIA-H) MRI Finding
ARIA are an identified risk with anti-amyloid antibodies, including gantenerumab. These changes can be identified on brain MRI. ARIA-H (H for hemosiderosis) are small foci of signal loss observed on MRI sequences sensitive for paramagnetic tissue properties and comprise cerebral microbleeds (small foci of bleeding in the brain parenchyma) and leptomeningeal hemosiderosis (small foci of bleeding on the surface of the brain). These changes also occur sporadically in AD.
Time frame: From Day 1 up to 14 weeks after the last dose of blinded study drug (up to 131 weeks)
DBT Period: Number of Participants With Injection-Site Reactions
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product or other protocol-imposed intervention, regardless of attribution. Local injection reactions (or injection site reactions) are defined as AEs related to the injection site that occur during or within 24 hours after study drug administration that are judged to be related to the study drug injection.
Time frame: From Day 1 up to 14 weeks after the last dose of blinded study drug (up to 131 weeks)
DBT Period: Number of Participants With Anti-Drug Antibodies (ADA) to Gantenerumab
The number of participants with positive results for ADA against gantenerumab at any of the post-baseline assessment time-points were reported. Participant with an ADA assay result from at least one post-baseline sample was defined as a post-baseline evaluable participant. Treatment Emergent ADA = A participant with a negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result.
Time frame: From Day 1 up to 14 weeks after the last dose of blinded study drug (up to 131 weeks)
DBT Period: Change From Baseline to Week 116 in Brain Amyloid Load as Measured by Amyloid Positron Emission Tomography (PET) Scan in a Subset of Participants
Brain amyloid load over time was assessed using \[18F\] florbetaben or \[18F\] flutemetamol tracers. These are PET radioligand selective to amyloid. Amyloid PET burden was measured in a composite region of interest (ROI) by using standardized uptake value ratio (SUVR) mapped to the centiloid scale. The weighted composite target region are composed of (both left and right side): frontal lobe, parietal lobe, temporal lobe lateral, cingulum posterior and anterior cingulate gyrus. The reference region used to normalize the composite region was the whole cerebellum. The centiloid scale anchor points are 0 and 100, where 0 represents a high-certainty amyloid negative scan and 100 represents the amount of global amyloid deposition found in a typical AD scan.
Time frame: Baseline, Week 116
DBT Period: Change From Baseline to Week 116 in Brain Tau Load, as Measured by Tau PET Scan in a Subset of Participants
Change in tau load= how much neurofibrillary tau pathology is present in brain assessed by PET Scan. \[18F\] GTP1 was the tau PET radioligand. Tau load was measured using SUVR in 4 composite target ROIs: Temporal composite target region (left \& right)=anterior \& posterior superior temporal gyrus, posterior temporal lobe, fusiform gyrus, \& middle \& inferior temporal gyrus; Medial temporal composite region excluding hippocampus (left \& right): amygdala, parahippocampus \& anterior medial \& lateral temporal lobe; Frontal lobe (left \& right) \& Parietal lobe (left \& right). Inferior cerebellar grey matter=reference region for calculating SUVRs for all 4 regions. Tau-PET-mITT analysis set=all participants in ITT analysis set who participated in Tau PET sub-study \& who had at least one Tau PET scan with a valid quantitative measurement \& who did not withdraw from Tau PET substudy before randomization. Overall number analyzed=number of participants with data available for analysis.
Time frame: Baseline, Week 116
DBT Period: Percent Change From Baseline to Week 116 in Cerebrospinal Fluid (CSF) Marker of Disease in a Subset of Participants - Total Tau (tTau)
CSF biomarker tTau has been considered as a general marker of neurodegeneration. An elevation in levels of tau, as well as specific pTau species, is thought to be a marker for progressive cellular degeneration in AD.
Time frame: Baseline, Week 116
DBT Period: Percent Change From Baseline to Week 116 in CSF Marker of Disease in a Subset of Participants - Phosphorylated Tau (pTau-181)
CSF phospho-tau is an indicator of neuronal injury and neurodegeneration. CSF biomarker tTau has been considered as a general marker of neurodegeneration. An elevation in levels of pTau species, is thought to be a marker for progressive cellular degeneration in AD.
Time frame: Baseline, Week 116
DBT Period: Percent Change From Baseline to Week 116 in CSF Marker of Disease in a Subset of Participants - Neurofilament Light Chain (NFL)
NFL is a neuronal cytoplasmic protein highly expressed in large, myelinated axons. Its levels increase in CSF and blood proportionally to the degree of axonal damage in a variety of neurological disorders, including AD.
Time frame: Baseline, Week 116
DBT Period: Percent Change From Baseline to Week 116 in CSF Marker of Disease in a Subset of Participants - Neurogranin
Time frame: Baseline, Week 116
China - DBT Period: Change From Baseline to Week 116 in ADAS-Cog13 Score
The ADAS-Cog13 total score includes all of the items in the ADAS-Cog11 in addition to delayed word recall and the number cancellation. For the ADAS-cog 13 the range is 0-85 (score range for Delayed Word Recall \[DWR\] score is 0-10 and for Number Cancellation \[NC\] is 0-5, thus the score is ADAS-cog 11\[0-70\] plus the scores for DWR and NC). A higher score indicates worse performance. A negative change from baseline indicates improvement in cognitive function.
Time frame: Baseline, Week 116
China - DBT Period: Change From Baseline to Week 116 in ADCS-ADL Total Score
ADCS-ADL is a 23-item rater-administered, ObsRO that captures a participant's ability to perform basic activities of daily living (e.g., eating and toileting) and more complex ADL or instrumental activities of daily living (iADL, e.g., using the telephone, managing finances, preparing a meal). Total score ranges from 0-78, with higher scores reflecting better functioning. A positive change from baseline indicates improvement.
Time frame: Baseline, Week 116
China - DBT Period: Change From Baseline to Week 116 in FAQ Score
FAQ is a rater-administered ObsRO (informant-based measure) that measures a participant's functional ability to perform complex higher-order activities. The observer provides performance ratings of the target person on ten complex higher-order activities. Total score that ranges from 0-30, with higher scores reflecting greater functional impairment. A negative change from baseline indicates improvement.
Time frame: Baseline, Week 116
China - DBT Period: DBT Period: Change From Baseline to Week 116 in MMSE Total Score
MMSE is a rater-administered PerfO that includes a set of standardized questions used to evaluate possible cognitive impairment and help stage the severity level of this impairment. The questions target six areas: orientation, registration, attention, short-term recall, language, and constructional praxis/visuospatial abilities. Total score ranges from 0-30, with lower scores indicating greater impairment. A positive change from baseline indicates improvement.
Time frame: Baseline, Week 116
China - DBT Period: Change From Baseline to Week 116 in ADAS-Cog11 Score
The ADAS-Cog11 was designed to measure cognitive symptom change in participants with AD and consisted of 11 tasks. The standard 11 items (and corresponding score range) were: word recall (0-10), commands (0-5), constructional praxis (0-5), naming objects and fingers (0-5), ideational praxis (0-5), orientation (0-8), word recognition (0-12), spoken language ability (0-5), comprehension of spoken language (0-5), word-finding difficulty (0-5), and remembering test instructions (0-5). The test included 7 performance items and 4 clinician-rated items. The ADAS-Cog11 total score was the sum of all 11 individual items, with a total score ranging from 0 (no impairment) to 70 (severe impairment). Higher scores indicated more severe cognitive impairment. A negative change from baseline indicates improvement.
Time frame: Baseline, Week 116
China - DBT Period: Change From Baseline to Week 116 in VFT Score
VFT is a rater administered PerfO that measures speed and flexibility of verbal thought with a total score that ranges from 0-99 (lower scores indicating lower performance). A positive change from baseline indicates improvement.
Time frame: Baseline, Week 116
China - DBT Period: Change From Baseline to Week 116 in the Coding (DSST) Subtest
Coding, also called DSST is a rater administered PerfO that measures speed of processing and associative memory with a total score that ranges from 0-135 (lower scores indicating lower performance). The DSST was adapted from the Wechsler Adult Intelligence Scale. The 120-second version of the test was used in this study. Positive change from baseline indicates improvement.
Time frame: Baseline, Week 116
China - DBT Period: Number of Participants With at Least One AE
An AE is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. Total number of participants with at least one event (AEs) have been reported here.
Time frame: From Day 1 up to 14 weeks after the last dose of blinded study drug (up to 124 weeks)
China - DBT Period: Number of Participants With Post-baseline Suicidal Ideation or Suicidal Behavior as Measured Using C-SSRS
C-SSRS=assessment tool used to assess lifetime suicidality of a participant (at baseline) as well as any new instances of suicidality (C-SSRS since last visit). Structured interview prompts recollection of suicidal ideation, including intensity of ideation, behavior, \& attempts with actual/potential lethality. Categories have binary responses (yes/no) \& include Wish to be Dead; Non-specific Active Suicidal Thoughts; Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; Active Suicidal Ideation with Some Intent to Act, without Specific Plan; Active Suicidal Ideation with Specific Plan and Intent, Preparatory Acts and Behavior; Aborted Attempt; Interrupted Attempt; Actual Attempt (non-fatal); Completed Suicide. Suicidal ideation/behavior is indicated by a "yes" answer to any of the listed categories. Score of 0 is assigned if no suicide risk is present. Score of 1 or higher= suicidal ideation or behavior. Categories with non-zero values are only reported here.
Time frame: From Day 1 up to 14 weeks after the last dose of blinded study drug (up to 124 weeks)
China - DBT Period: Number of Participants With at Least One ARIA-E MRI Finding
ARIA are an identified risk with anti-amyloid antibodies, including gantenerumab. These changes can be identified on brain MRI. In ARIA-E, (E for oedema or effusion), oedema can be seen in different areas of the brain on MRI, representing fluid leakage into the brain parenchyma or sulcal spaces.
Time frame: From Day 1 up to 14 weeks after the last dose of blinded study drug (up to 124 weeks)
China - DBT Period: Number of Participants With at Least One ARIA-H MRI Finding
ARIA are an identified risk with anti-amyloid antibodies, including gantenerumab. These changes can be identified on brain MRI. ARIA-H (H for hemosiderosis) are small foci of signal loss observed on MRI sequences sensitive for paramagnetic tissue properties and comprise cerebral microbleeds (small foci of bleeding in the brain parenchyma) and leptomeningeal hemosiderosis (small foci of bleeding on the surface of the brain). These changes also occur sporadically in AD.
Time frame: From Day 1 up to 14 weeks after the last dose of blinded study drug (up to 124 weeks)
China - DBT Period: Number of Participants With Injection-Site Reactions
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product or other protocol-imposed intervention, regardless of attribution. Local injection reactions (or injection site reactions) are defined as AEs related to the injection site that occur during or within 24 hours after study drug administration that are judged to be related to the study drug injection.
Time frame: From Day 1 up to 14 weeks after the last dose of blinded study drug (up to 124 weeks)
OLE Period: Number of Participants With at Least One AEs
An AE is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution.
Time frame: From day of first dose in OLE period up to 14 weeks after the last OLE dose (up to 68 weeks)
OLE Period: Number of Participants With Post-baseline Suicidal Ideation or Suicidal Behavior as Measured Using C-SSRS
C-SSRS=assessment tool used to assess lifetime suicidality of a participant (at baseline) as well as any new instances of suicidality (C-SSRS since last visit). Structured interview prompts recollection of suicidal ideation, including intensity of ideation, behavior, \& attempts with actual/potential lethality. Categories have binary responses (yes/no) \& include Wish to be Dead; Non-specific Active Suicidal Thoughts; Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; Active Suicidal Ideation with Some Intent to Act, without Specific Plan; Active Suicidal Ideation with Specific Plan and Intent, Preparatory Acts and Behavior; Aborted Attempt; Interrupted Attempt; Actual Attempt (non-fatal); Completed Suicide. Suicidal ideation/behavior is indicated by a "yes" answer to any of the listed categories. Score of 0 is assigned if no suicide risk is present. Score of 1 or higher= suicidal ideation or behavior. Categories with non-zero values are only reported here.
Time frame: From day of first dose in OLE period up to 14 weeks after the last OLE dose (up to 68 weeks)
OLE Period: Number of Participants With at Least One ARIA-H MRI Finding
ARIA are an identified risk with anti-amyloid antibodies, including gantenerumab. These changes can be identified on brain MRI. ARIA-H (H for hemosiderosis) are small foci of signal loss observed on MRI sequences sensitive for paramagnetic tissue properties and comprise cerebral microbleeds (small foci of bleeding in the brain parenchyma) and leptomeningeal hemosiderosis (small foci of bleeding on the surface of the brain). These changes also occur sporadically in AD.
Time frame: From day of first dose in OLE period up to 14 weeks after the last OLE dose (up to 68 weeks)
OLE Period: Number of Participants With at Least One ARIA-E MRI Finding
ARIA are an identified risk with anti-amyloid antibodies, including gantenerumab. These changes can be identified on brain MRI. In ARIA-E, (E for oedema or effusion), oedema can be seen in different areas of the brain on MRI, representing fluid leakage into the brain parenchyma or sulcal spaces.
Time frame: From day of first dose in OLE period up to 14 weeks after the last OLE dose (up to 68 weeks)
Participants were enrolled in this study at 137 sites across 15 countries (Australia, Brazil, Canada, China, France, Germany, Hungary, Italy, Japan, Lithuania, Peru, Russia, Taiwan, Spain, and the United States) during the global phase. Participants were enrolled at 21 sites in China during the China extension phase of the study. The open-label period in China was not started as the study was terminated early by the Sponsor.
| Milestone | Global - DBT Period: Placebo | Global - DBT Period: Gantenerumab | China Extension - DBT Period: Placebo | China Extension - DBT Period: Gantenerumab | Global - OLE Period: Placebo (DBT) to Gantenerumab | Global - OLE Period: Gantenerumab (DBT) to Gantenerumab |
|---|---|---|---|---|---|---|
| Started | 486 | 499 | 33 | 35 | 0 | 0 |
| Intent-to-treat (itt) analysis set | 485 | 499 | 0 | 0 | 0 | 0 |
| Safety-evaluable (se) analysis set | 481 | 503 | 0 | 0 | 0 | 0 |
| Itt analysis set (china) | 0 | 0 | 33 | 35 | 0 | 0 |
| Se analysis set (china) | 0 | 0 | 33 | 35 | 0 | 0 |
| Safety magnetic resonance imaging (mri)-evaluable (semri) analysis set | 476 | 497 | 0 | 0 | 0 | 0 |
| Completed | 387 | 375 | 0 | 0 | 0 | 0 |
| Not completed | 99 | 124 | 33 | 35 | 0 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 30 | 35 | 0 | 0 |
| Withdrew: Reason not specified | 17 | 16 | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 56 | 63 | 2 | 0 | 0 | 0 |
| Withdrew: Protocol deviation | 4 | 3 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 3 | 11 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 10 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 7 | 29 | 0 | 0 | 0 | 0 |
| Withdrew: Randomized, but not treated | 1 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Global - DBT Period: Placebo | Global - DBT Period: Gantenerumab | China Extension - DBT Period: Placebo | China Extension - DBT Period: Gantenerumab | Global - OLE Period: Placebo (DBT) to Gantenerumab | Global - OLE Period: Gantenerumab (DBT) to Gantenerumab |
|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 10 | 19 |
| Se analysis set | 0 | 0 | 0 | 0 | 9 | 20 |
| Completed | 0 | 0 | 0 | 0 | 7 | 17 |
| Not completed | 0 | 0 | 0 | 0 | 3 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 1 | 2 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 1 | 0 |
CDR was derived through semi-structured interview with the participant and an appropriate informant, and it rated impairment across six domains: memory, orientation, judgment, and problem solving, community affairs, home and hobbies, and personal care on a 5-point scale for which 0=no impairment, 0.5=questionable impairment, and 1, 2, and 3=mild, moderate, and severe impairment, respectively. The CDR-SB is based on summing each of the domain box scores with total score ranging from 0-18 with higher scores reflecting greater cognitive and functional impairment. A negative change from baseline indicates improvement.
| score on a scale | Global - DBT Period: Placebo | Global - DBT Period: Gantenerumab |
|---|---|---|
| DBT Period: Change From Baseline to Week 116 in Global Outcome, as Measured by CDR-SB | 3.65 ± 0.16 | 3.35 ± 0.14 |
CDR was derived through semi-structured interview with the participant and an appropriate informant, and it rated impairment across six domains: memory, orientation, judgment, and problem solving, community affairs, home and hobbies, and personal care on a 5-point scale for which 0=no impairment, 0.5=questionable impairment, and 1, 2, and 3=mild, moderate, and severe impairment, respectively. The CDR-SB is based on summing each of the domain box scores with total score ranging from 0-18 with higher scores reflecting greater cognitive and functional impairment. A negative change from baseline indicates improvement.
No measurements were reported for this outcome.
The ADAS-Cog13 total score includes all of the items in the ADAS-Cog11 in addition to delayed word recall and the number cancellation. For the ADAS-cog 13 the range is 0-85 (score range for Delayed Word Recall \[DWR\] score is 0-10 and for Number Cancellation \[NC\] is 0-5, thus the score is ADAS-cog 11\[0-70\] plus the scores for DWR and NC). A higher score indicates worse performance. A negative change from baseline indicates improvement in cognitive function.
| score on a scale | Global - DBT Period: Placebo | Global - DBT Period: Gantenerumab |
|---|---|---|
| DBT Period: Change From Baseline to Week 116 in Alzheimer Disease Assessment Scale-Cognition Subscale 13 (ADAS-Cog13) Score | 9.82 ± 0.57 | 8.57 ± 0.47 |
ADCS-ADL is a 23-item rater-administered, observer-reported outcome (ObsRO) that captures a participant's ability to perform basic activities of daily living (e.g., eating and toileting) and more complex ADL or instrumental activities of daily living (iADL, e.g., using the telephone, managing finances, preparing a meal). Total score ranges from 0-78, with higher scores reflecting better functioning. A positive change from baseline indicates improvement.
| score on a scale | Global - DBT Period: Placebo | Global - DBT Period: Gantenerumab |
|---|---|---|
| DBT Period: Change From Baseline to Week 116 in Alzheimer's Disease Cooperative Study- Activities of Daily Living (ADCS-ADL) Total Score | -12.32 ± 0.68 | -11.21 ± 0.60 |
FAQ is a rater-administered ObsRO (informant-based measure) that measures a participant's functional ability to perform complex higher-order activities. The observer provides performance ratings of the target person on ten complex higher-order activities. Total score that ranges from 0-30, with higher scores reflecting greater functional impairment. A negative change from baseline indicates improvement.
| score on a scale | Global - DBT Period: Placebo | Global - DBT Period: Gantenerumab |
|---|---|---|
| DBT Period: Change From Baseline to Week 116 in Functional Activities Questionnaire (FAQ) Score | 8.13 ± 0.33 | 7.28 ± 0.30 |
MMSE is a rater-administered performance-based outcome (PerfO) that includes a set of standardized questions used to evaluate possible cognitive impairment and help stage the severity level of this impairment. The questions target six areas: orientation, registration, attention, short-term recall, language, and constructional praxis/visuospatial abilities. Total score ranges from 0-30, with lower scores indicating greater impairment. A positive change from baseline indicates improvement.
| score on a scale | Global - DBT Period: Placebo | Global - DBT Period: Gantenerumab |
|---|---|---|
| DBT Period: Change From Baseline to Week 116 in Mini-Mental State Examination (MMSE) Total Score | -5.18 ± 0.25 | -4.86 ± 0.23 |
The ADAS-Cog11 was designed to measure cognitive symptom change in participants with Alzheimer's Disease (AD) and consisted of 11 tasks. The standard 11 items (and corresponding score range) were: word recall (0-10), commands (0-5), constructional praxis (0-5), naming objects and fingers (0-5), ideational praxis (0-5), orientation (0-8), word recognition (0-12), spoken language ability (0-5), comprehension of spoken language (0-5), word-finding difficulty (0-5), and remembering test instructions (0-5). The test included 7 performance items and 4 clinician-rated items. The ADAS-Cog11 total score was the sum of all 11 individual items, with a total score ranging from 0 (no impairment) to 70 (severe impairment). Higher scores indicated more severe cognitive impairment. A negative change from baseline indicates improvement.
| score on a scale | Global - DBT Period: Placebo | Global - DBT Period: Gantenerumab |
|---|---|---|
| DBT Period: Change From Baseline to Week 116 in Alzheimer Disease Assessment Scale-Cognition Subscale 11 (ADAS-Cog11) Score | 8.42 ± 0.52 | 7.44 ± 0.43 |
VFT is a rater administered PerfO that measures speed and flexibility of verbal thought with a total score that ranges from 0-99 (lower scores indicating lower performance). A positive change from baseline indicates improvement.
| score on a scale | Global - DBT Period: Placebo | Global - DBT Period: Gantenerumab |
|---|---|---|
| DBT Period: Change From Baseline to Week 116 in Verbal Fluency Task (VFT) Score | -3.46 ± 0.31 | -3.53 ± 0.30 |
Coding, also called DSST is a rater administered PerfO that measures speed of processing and associative memory with a total score that ranges from 0-135 (lower scores indicating lower performance). The DSST was adapted from the Wechsler Adult Intelligence Scale. The 120-second version of the test was used in this study. Positive change from baseline indicates improvement.
| score on a scale | Global - DBT Period: Placebo | Global - DBT Period: Gantenerumab |
|---|---|---|
| DBT Period: Change From Baseline to Week 116 in the Coding (Digit Symbol Substitution Test [DSST]) Subtest | -6.47 ± 0.64 | -6.27 ± 0.54 |
The ADCS-iADL measures activities such as using the telephone, shopping and preparing a meal. The ADCS-iADL consists of 16 questions with a score range of 0 to 56 where a higher score represents better function. Positive change from baseline indicates improvement.
| score on a scale | Global - DBT Period: Placebo | Global - DBT Period: Gantenerumab |
|---|---|---|
| DBT Period: Change From Baseline to Week 116 in Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-iADL) Instrumental Score | -10.80 ± 0.56 | -9.80 ± 0.51 |
An AE is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution.
| Participants | Global - DBT Period: Placebo | Global - DBT Period: Gantenerumab |
|---|---|---|
| DBT Period: Number of Participants With at Least One Adverse Event (AE) | 423 | 454 |
C-SSRS=assessment tool used to assess lifetime suicidality of a participant (at baseline) as well as any new instances of suicidality (C-SSRS since last visit). Structured interview prompts recollection of suicidal ideation, including intensity of ideation, behavior, \& attempts with actual/potential lethality. Categories have binary responses (yes/no) \& include Wish to be Dead; Non-specific Active Suicidal Thoughts; Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; Active Suicidal Ideation with Some Intent to Act, without Specific Plan; Active Suicidal Ideation with Specific Plan and Intent, Preparatory Acts and Behavior; Aborted Attempt; Interrupted Attempt; Actual Attempt (non-fatal); Completed Suicide. Suicidal ideation/behavior is indicated by a "yes" answer to any of the listed categories. Score of 0 is assigned if no suicide risk is present. Score of 1 or higher= suicidal ideation or behavior. Categories with non-zero values are only reported here.
| Participants | Global - DBT Period: Placebo | Global - DBT Period: Gantenerumab |
|---|---|---|
| Suicidal Ideation: Passive | 13 | 17 |
| Suicidal Ideation: Active-Nonspecific | 1 | 3 |
| Suicidal Ideation: Active-Method, But No Intent or Plan | 6 | 3 |
| Suicidal Ideation: Active-Method and Intent, But No Plan | 2 | 0 |
| Suicidal Ideation: Active-Method, Intent, and Plan | 2 | 0 |
| Suicidal Ideation: No Event | 443 | 466 |
| Suicidal Behavior: Interrupted Attempt | 0 | 1 |
| Suicidal Behavior: No Event | 467 | 488 |
| Self-injurious Behavior Without Suicidal Intent: No Event | 467 | 489 |
ARIA are an identified risk with anti-amyloid antibodies, including gantenerumab. These changes can be identified on brain MRI. In ARIA-E, (E for oedema or effusion), oedema can be seen in different areas of the brain on MRI, representing fluid leakage into the brain parenchyma or sulcal spaces.
| Participants | Global - DBT Period: Placebo | Global - DBT Period: Gantenerumab |
|---|---|---|
| DBT Period: Number of Participants With at Least One Amyloid-Related Imaging Abnormalities-Edema (ARIA-E) Magnetic Resonance Imaging (MRI) Finding | 5 | 105 |
ARIA are an identified risk with anti-amyloid antibodies, including gantenerumab. These changes can be identified on brain MRI. ARIA-H (H for hemosiderosis) are small foci of signal loss observed on MRI sequences sensitive for paramagnetic tissue properties and comprise cerebral microbleeds (small foci of bleeding in the brain parenchyma) and leptomeningeal hemosiderosis (small foci of bleeding on the surface of the brain). These changes also occur sporadically in AD.
| Participants | Global - DBT Period: Placebo | Global - DBT Period: Gantenerumab |
|---|---|---|
| DBT Period: Number of Participants With at Least One Amyloid-Related Imaging Abnormalities-Haemosiderin Deposition (ARIA-H) MRI Finding | 6 | 40 |
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product or other protocol-imposed intervention, regardless of attribution. Local injection reactions (or injection site reactions) are defined as AEs related to the injection site that occur during or within 24 hours after study drug administration that are judged to be related to the study drug injection.
| Participants | Global - DBT Period: Placebo | Global - DBT Period: Gantenerumab |
|---|---|---|
| DBT Period: Number of Participants With Injection-Site Reactions | 43 | 94 |
The number of participants with positive results for ADA against gantenerumab at any of the post-baseline assessment time-points were reported. Participant with an ADA assay result from at least one post-baseline sample was defined as a post-baseline evaluable participant. Treatment Emergent ADA = A participant with a negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result.
| Participants | Global - DBT Period: Gantenerumab |
|---|---|
| DBT Period: Number of Participants With Anti-Drug Antibodies (ADA) to Gantenerumab | 10 |
Brain amyloid load over time was assessed using \[18F\] florbetaben or \[18F\] flutemetamol tracers. These are PET radioligand selective to amyloid. Amyloid PET burden was measured in a composite region of interest (ROI) by using standardized uptake value ratio (SUVR) mapped to the centiloid scale. The weighted composite target region are composed of (both left and right side): frontal lobe, parietal lobe, temporal lobe lateral, cingulum posterior and anterior cingulate gyrus. The reference region used to normalize the composite region was the whole cerebellum. The centiloid scale anchor points are 0 and 100, where 0 represents a high-certainty amyloid negative scan and 100 represents the amount of global amyloid deposition found in a typical AD scan.
| score on a scale | Global - DBT Period: Placebo | Global - DBT Period: Gantenerumab |
|---|---|---|
| DBT Period: Change From Baseline to Week 116 in Brain Amyloid Load as Measured by Amyloid Positron Emission Tomography (PET) Scan in a Subset of Participants | 9.06 ± 3.046 | -57.38 ± 2.841 |
Change in tau load= how much neurofibrillary tau pathology is present in brain assessed by PET Scan. \[18F\] GTP1 was the tau PET radioligand. Tau load was measured using SUVR in 4 composite target ROIs: Temporal composite target region (left \& right)=anterior \& posterior superior temporal gyrus, posterior temporal lobe, fusiform gyrus, \& middle \& inferior temporal gyrus; Medial temporal composite region excluding hippocampus (left \& right): amygdala, parahippocampus \& anterior medial \& lateral temporal lobe; Frontal lobe (left \& right) \& Parietal lobe (left \& right). Inferior cerebellar grey matter=reference region for calculating SUVRs for all 4 regions. Tau-PET-mITT analysis set=all participants in ITT analysis set who participated in Tau PET sub-study \& who had at least one Tau PET scan with a valid quantitative measurement \& who did not withdraw from Tau PET substudy before randomization. Overall number analyzed=number of participants with data available for analysis.
| SUVR | Global - DBT Period: Placebo | Global - DBT Period: Gantenerumab |
|---|---|---|
| ROI: Temporal Composite Region | 0.12 ± 0.018 | 0.13 ± 0.014 |
| ROI: Medial Temporal Composite Region [not including the Hippocampus] | 0.08 ± 0.014 | 0.09 ± 0.011 |
| ROI: Frontal Lobe | 0.08 ± 0.012 | 0.08 ± 0.009 |
| ROI: Parietal Lobe | 0.09 ± 0.020 | 0.09 ± 0.016 |
CSF biomarker tTau has been considered as a general marker of neurodegeneration. An elevation in levels of tau, as well as specific pTau species, is thought to be a marker for progressive cellular degeneration in AD.
| percent change in tTau | Global - DBT Period: Placebo | Global - DBT Period: Gantenerumab |
|---|---|---|
| DBT Period: Percent Change From Baseline to Week 116 in Cerebrospinal Fluid (CSF) Marker of Disease in a Subset of Participants - Total Tau (tTau) | 3.2 (-1.74 to 8.37) | -16.6 (-20.40 to -12.54) |
CSF phospho-tau is an indicator of neuronal injury and neurodegeneration. CSF biomarker tTau has been considered as a general marker of neurodegeneration. An elevation in levels of pTau species, is thought to be a marker for progressive cellular degeneration in AD.
| percent change in pTau-181 | Global - DBT Period: Placebo | Global - DBT Period: Gantenerumab |
|---|---|---|
| DBT Period: Percent Change From Baseline to Week 116 in CSF Marker of Disease in a Subset of Participants - Phosphorylated Tau (pTau-181) | 1.1 (-3.76 to 6.20) | -25.2 (-28.65 to -21.49) |
NFL is a neuronal cytoplasmic protein highly expressed in large, myelinated axons. Its levels increase in CSF and blood proportionally to the degree of axonal damage in a variety of neurological disorders, including AD.
| percent change in NFL | Global - DBT Period: Placebo | Global - DBT Period: Gantenerumab |
|---|---|---|
| DBT Period: Percent Change From Baseline to Week 116 in CSF Marker of Disease in a Subset of Participants - Neurofilament Light Chain (NFL) | 15.8 (9.67 to 22.32) | 12.1 (6.41 to 18.11) |
| percent change in neurogranin | Global - DBT Period: Placebo | Global - DBT Period: Gantenerumab |
|---|---|---|
| DBT Period: Percent Change From Baseline to Week 116 in CSF Marker of Disease in a Subset of Participants - Neurogranin | -0.6 (-5.93 to 5.05) | -22.3 (-26.28 to -18.13) |
The ADAS-Cog13 total score includes all of the items in the ADAS-Cog11 in addition to delayed word recall and the number cancellation. For the ADAS-cog 13 the range is 0-85 (score range for Delayed Word Recall \[DWR\] score is 0-10 and for Number Cancellation \[NC\] is 0-5, thus the score is ADAS-cog 11\[0-70\] plus the scores for DWR and NC). A higher score indicates worse performance. A negative change from baseline indicates improvement in cognitive function.
No measurements were reported for this outcome.
ADCS-ADL is a 23-item rater-administered, ObsRO that captures a participant's ability to perform basic activities of daily living (e.g., eating and toileting) and more complex ADL or instrumental activities of daily living (iADL, e.g., using the telephone, managing finances, preparing a meal). Total score ranges from 0-78, with higher scores reflecting better functioning. A positive change from baseline indicates improvement.
No measurements were reported for this outcome.
FAQ is a rater-administered ObsRO (informant-based measure) that measures a participant's functional ability to perform complex higher-order activities. The observer provides performance ratings of the target person on ten complex higher-order activities. Total score that ranges from 0-30, with higher scores reflecting greater functional impairment. A negative change from baseline indicates improvement.
No measurements were reported for this outcome.
MMSE is a rater-administered PerfO that includes a set of standardized questions used to evaluate possible cognitive impairment and help stage the severity level of this impairment. The questions target six areas: orientation, registration, attention, short-term recall, language, and constructional praxis/visuospatial abilities. Total score ranges from 0-30, with lower scores indicating greater impairment. A positive change from baseline indicates improvement.
No measurements were reported for this outcome.
The ADAS-Cog11 was designed to measure cognitive symptom change in participants with AD and consisted of 11 tasks. The standard 11 items (and corresponding score range) were: word recall (0-10), commands (0-5), constructional praxis (0-5), naming objects and fingers (0-5), ideational praxis (0-5), orientation (0-8), word recognition (0-12), spoken language ability (0-5), comprehension of spoken language (0-5), word-finding difficulty (0-5), and remembering test instructions (0-5). The test included 7 performance items and 4 clinician-rated items. The ADAS-Cog11 total score was the sum of all 11 individual items, with a total score ranging from 0 (no impairment) to 70 (severe impairment). Higher scores indicated more severe cognitive impairment. A negative change from baseline indicates improvement.
No measurements were reported for this outcome.
VFT is a rater administered PerfO that measures speed and flexibility of verbal thought with a total score that ranges from 0-99 (lower scores indicating lower performance). A positive change from baseline indicates improvement.
No measurements were reported for this outcome.
Coding, also called DSST is a rater administered PerfO that measures speed of processing and associative memory with a total score that ranges from 0-135 (lower scores indicating lower performance). The DSST was adapted from the Wechsler Adult Intelligence Scale. The 120-second version of the test was used in this study. Positive change from baseline indicates improvement.
No measurements were reported for this outcome.
An AE is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution. Total number of participants with at least one event (AEs) have been reported here.
| Participants | China Extension - DBT Period: Placebo | China Extension - DBT Period: Gantenerumab |
|---|---|---|
| China - DBT Period: Number of Participants With at Least One AE | 17 | 24 |
C-SSRS=assessment tool used to assess lifetime suicidality of a participant (at baseline) as well as any new instances of suicidality (C-SSRS since last visit). Structured interview prompts recollection of suicidal ideation, including intensity of ideation, behavior, \& attempts with actual/potential lethality. Categories have binary responses (yes/no) \& include Wish to be Dead; Non-specific Active Suicidal Thoughts; Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; Active Suicidal Ideation with Some Intent to Act, without Specific Plan; Active Suicidal Ideation with Specific Plan and Intent, Preparatory Acts and Behavior; Aborted Attempt; Interrupted Attempt; Actual Attempt (non-fatal); Completed Suicide. Suicidal ideation/behavior is indicated by a "yes" answer to any of the listed categories. Score of 0 is assigned if no suicide risk is present. Score of 1 or higher= suicidal ideation or behavior. Categories with non-zero values are only reported here.
| Participants | China Extension - DBT Period: Placebo | China Extension - DBT Period: Gantenerumab |
|---|---|---|
| Suicidal Ideation: Passive | 1 | 1 |
| Suicidal Ideation: Active-Nonspecific (no method, intent, or plan) | 0 | 1 |
| Suicidal Ideation: Active-Method and intent, but no plan | 1 | 0 |
| Suicidal Ideation: No Event | 23 | 28 |
| Suicidal Behavior: No Event | 25 | 30 |
| Self-injurious Behavior Without Suicidal Intent: No event | 25 | 30 |
ARIA are an identified risk with anti-amyloid antibodies, including gantenerumab. These changes can be identified on brain MRI. In ARIA-E, (E for oedema or effusion), oedema can be seen in different areas of the brain on MRI, representing fluid leakage into the brain parenchyma or sulcal spaces.
| Participants | China Extension - DBT Period: Placebo | China Extension - DBT Period: Gantenerumab |
|---|---|---|
| China - DBT Period: Number of Participants With at Least One ARIA-E MRI Finding | 1 | 4 |
ARIA are an identified risk with anti-amyloid antibodies, including gantenerumab. These changes can be identified on brain MRI. ARIA-H (H for hemosiderosis) are small foci of signal loss observed on MRI sequences sensitive for paramagnetic tissue properties and comprise cerebral microbleeds (small foci of bleeding in the brain parenchyma) and leptomeningeal hemosiderosis (small foci of bleeding on the surface of the brain). These changes also occur sporadically in AD.
| Participants | China Extension - DBT Period: Placebo | China Extension - DBT Period: Gantenerumab |
|---|---|---|
| China - DBT Period: Number of Participants With at Least One ARIA-H MRI Finding | 0 | 1 |
An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of an investigational product or other protocol-imposed intervention, regardless of attribution. Local injection reactions (or injection site reactions) are defined as AEs related to the injection site that occur during or within 24 hours after study drug administration that are judged to be related to the study drug injection.
| Participants | China Extension - DBT Period: Placebo | China Extension - DBT Period: Gantenerumab |
|---|---|---|
| China - DBT Period: Number of Participants With Injection-Site Reactions | 0 | 0 |
An AE is any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, regardless of causal attribution.
| Participants | Global - OLE Period: Placebo (DBT) to Gantenerumab | Global - OLE Period: Gantenerumab (DBT) to Gantenerumab |
|---|---|---|
| OLE Period: Number of Participants With at Least One AEs | 8 | 16 |
C-SSRS=assessment tool used to assess lifetime suicidality of a participant (at baseline) as well as any new instances of suicidality (C-SSRS since last visit). Structured interview prompts recollection of suicidal ideation, including intensity of ideation, behavior, \& attempts with actual/potential lethality. Categories have binary responses (yes/no) \& include Wish to be Dead; Non-specific Active Suicidal Thoughts; Active Suicidal Ideation with Any Methods (Not Plan) without Intent to Act; Active Suicidal Ideation with Some Intent to Act, without Specific Plan; Active Suicidal Ideation with Specific Plan and Intent, Preparatory Acts and Behavior; Aborted Attempt; Interrupted Attempt; Actual Attempt (non-fatal); Completed Suicide. Suicidal ideation/behavior is indicated by a "yes" answer to any of the listed categories. Score of 0 is assigned if no suicide risk is present. Score of 1 or higher= suicidal ideation or behavior. Categories with non-zero values are only reported here.
| Participants | Global - OLE Period: Placebo (DBT) to Gantenerumab | Global - OLE Period: Gantenerumab (DBT) to Gantenerumab |
|---|---|---|
| Suicidal Ideation: Active-Method, but no intent or plan | 0 | 1 |
| Suicidal Ideation: No Event | 6 | 18 |
| Suicidal Behavior: No Event | 6 | 19 |
| Self-injurious Behavior Without Suicidal Intent: No event | 6 | 19 |
ARIA are an identified risk with anti-amyloid antibodies, including gantenerumab. These changes can be identified on brain MRI. ARIA-H (H for hemosiderosis) are small foci of signal loss observed on MRI sequences sensitive for paramagnetic tissue properties and comprise cerebral microbleeds (small foci of bleeding in the brain parenchyma) and leptomeningeal hemosiderosis (small foci of bleeding on the surface of the brain). These changes also occur sporadically in AD.
| Participants | Global - OLE Period: Placebo (DBT) to Gantenerumab | Global - OLE Period: Gantenerumab (DBT) to Gantenerumab |
|---|---|---|
| OLE Period: Number of Participants With at Least One ARIA-H MRI Finding | 1 | 1 |
ARIA are an identified risk with anti-amyloid antibodies, including gantenerumab. These changes can be identified on brain MRI. In ARIA-E, (E for oedema or effusion), oedema can be seen in different areas of the brain on MRI, representing fluid leakage into the brain parenchyma or sulcal spaces.
| Participants | Global - OLE Period: Placebo (DBT) to Gantenerumab | Global - OLE Period: Gantenerumab (DBT) to Gantenerumab |
|---|---|---|
| OLE Period: Number of Participants With at Least One ARIA-E MRI Finding | 3 | 2 |
Collected over Global: DBT: Day 1 up to 14 weeks post last dose of blinded study drug (up to 131 weeks), OLE: Day 1 of OLE period up to 14 weeks post last OLE dose (up to 68 weeks); China DBT: Day 1 up to 14 weeks post last dose of blinded study drug (up to 124 weeks) All cause mortality: DBT: Day 1 up to the end of study (up to approximately 164 weeks); OLE period: From OLE Day 1 up to the end of the study (up to approximately 86 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Global - DBT Period: Placebo | 11/481 (2.3%) | 95/481 (19.8%) | 329/481 (68.4%) |
| Global - DBT Period: Gantenerumab | 3/503 (0.6%) | 76/503 (15.1%) | 366/503 (72.8%) |
| China Extension - DBT Period: Placebo | 0/33 (0%) | 0/33 (0%) | 11/33 (33.3%) |
| China Extension - DBT Period: Gantenerumab | 0/35 (0%) | 2/35 (5.7%) | 20/35 (57.1%) |
| Global - OLE Period: Placebo (DBT) to Gantenerumab | 1/9 (11.1%) | 2/9 (22.2%) | 8/9 (88.9%) |
| Global - OLE Period: Gantenerumab (DBT) to Gantenerumab | 0/20 (0%) | 2/20 (10%) | 16/20 (80%) |
| Event | Global - DBT Period: Placebo | Global - DBT Period: Gantenerumab | China Extension - DBT Period: Placebo | China Extension - DBT Period: Gantenerumab | Global - OLE Period: Placebo (DBT) to Gantenerumab | Global - OLE Period: Gantenerumab (DBT) to Gantenerumab |
|---|---|---|---|---|---|---|
| Traumatic intracranial haemorrhageInjury, poisoning and procedural complications | 0/481 | 0/503 | 0/33 | 0/35 | 1/9 | 0/20 |
| SyncopeNervous system disorders | 2/481 | 1/503 | 0/33 | 0/35 | 1/9 | 0/20 |
| Toxic encephalopathyNervous system disorders | 0/481 | 0/503 | 0/33 | 0/35 | 1/9 | 0/20 |
| Upper limb fractureInjury, poisoning and procedural complications | 0/481 | 1/503 | 0/33 | 0/35 | 0/9 | 1/20 |
| SeizureNervous system disorders | 0/481 | 0/503 | 0/33 | 0/35 | 0/9 | 1/20 |
| COVID-19Infections and infestations | 9/481 | 3/503 | 0/33 | 1/35 | 0/9 | 0/20 |
| UreterolithiasisRenal and urinary disorders | 1/481 | 0/503 | 0/33 | 1/35 | 0/9 | 0/20 |
| Amyloid related imaging abnormality-oedema/effusionNervous system disorders | 0/481 | 7/503 | 0/33 | 0/35 | 0/9 | 0/20 |
| FallInjury, poisoning and procedural complications | 2/481 | 6/503 | 0/33 | 0/35 | 0/9 | 0/20 |
| PneumoniaInfections and infestations | 5/481 | 0/503 | 0/33 | 0/35 | 0/9 | 0/20 |
| Event | Global - DBT Period: Placebo | Global - DBT Period: Gantenerumab | China Extension - DBT Period: Placebo | China Extension - DBT Period: Gantenerumab | Global - OLE Period: Placebo (DBT) to Gantenerumab | Global - OLE Period: Gantenerumab (DBT) to Gantenerumab |
|---|---|---|---|---|---|---|
| Amyloid related imaging abnormality-oedema/effusionNervous system disorders | 5/481 | 102/503 | 1/33 | 4/35 | 3/9 | 2/20 |
| FallInjury, poisoning and procedural complications | 62/481 | 60/503 | 0/33 | 0/35 | 2/9 | 1/20 |
| HypotensionVascular disorders | 7/481 | 12/503 | 0/33 | 0/35 | 2/9 | 0/20 |
| Injection site reactionGeneral disorders | 43/481 | 94/503 | 0/33 | 0/35 | 1/9 | 1/20 |
| HeadacheNervous system disorders | 42/481 | 60/503 | 1/33 | 1/35 | 0/9 | 1/20 |
| COVID-19Infections and infestations | 35/481 | 26/503 | 3/33 | 4/35 | 1/9 | 1/20 |
| Cardiac failure chronicCardiac disorders | 1/481 | 0/503 | 0/33 | 0/35 | 1/9 | 0/20 |
| Myocardial ischaemiaCardiac disorders | 1/481 | 0/503 | 0/33 | 0/35 | 1/9 | 0/20 |
| GingivitisInfections and infestations | 1/481 | 1/503 | 0/33 | 0/35 | 1/9 | 0/20 |
| Urinary tract infectionInfections and infestations | 28/481 | 30/503 | 0/33 | 1/35 | 1/9 | 2/20 |
ITT analysis set included all participants randomized during the global phase, who received at least one dose of study drug. ITT analysis set (China) included all participants enrolled in China in the China extension phase who received at least one dose of study drug.
| Age, Continuous(years) | Global - DBT Period: Placebo | Global - DBT Period: Gantenerumab | China Extension - DBT Period: Placebo | China Extension - DBT Period: Gantenerumab | Total |
|---|---|---|---|---|---|
| Mean | 72.1 ± 7.8 | 71.1 ± 7.9 | 65.9 ± 8.5 | 68.5 ± 7.3 | 71.4 ± 7.9 |
| Sex: Female, Male(Participants) | Global - DBT Period: Placebo | Global - DBT Period: Gantenerumab | China Extension - DBT Period: Placebo | China Extension - DBT Period: Gantenerumab | Total |
|---|---|---|---|---|---|
| Female | 255 | 290 | 16 | 18 | 579 |
| Male | 230 | 209 | 17 | 17 | 473 |
| Ethnicity (NIH/OMB)(Participants) | Global - DBT Period: Placebo | Global - DBT Period: Gantenerumab | China Extension - DBT Period: Placebo | China Extension - DBT Period: Gantenerumab | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 58 | 52 | 0 | 0 | 110 |
| Not Hispanic or Latino | 422 | 439 | 32 | 34 | 927 |
| Unknown or Not Reported | 5 | 8 | 1 | 1 | 15 |
| Race (NIH/OMB)(Participants) | Global - DBT Period: Placebo | Global - DBT Period: Gantenerumab | China Extension - DBT Period: Placebo | China Extension - DBT Period: Gantenerumab | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 18 | 18 | 0 | 0 | 36 |
| Asian | 53 | 52 | 33 | 35 | 173 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 6 | 1 | 0 | 0 | 7 |
| White | 398 | 414 | 0 | 0 | 812 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 10 | 14 | 0 | 0 | 24 |
| China Extension: Clinical Dementia Rating-Sum of Boxes (CDR-SB)(score on a scale) | Global - DBT Period: Placebo | Global - DBT Period: Gantenerumab | China Extension - DBT Period: Placebo | China Extension - DBT Period: Gantenerumab | Total |
|---|---|---|---|---|---|
| Mean | — | — | 3.29 ± 1.22 | 3.69 ± 1.50 | 3.49 ± 1.38 |
| DBT Period: CDR-SB(score on a scale) | Global - DBT Period: Placebo | Global - DBT Period: Gantenerumab | China Extension - DBT Period: Placebo | China Extension - DBT Period: Gantenerumab | Total |
|---|---|---|---|---|---|
| Mean | 3.71 ± 1.67 | 3.71 ± 1.57 | — | — | 3.71 ± 1.62 |
Showing the first 100 of 172 sites across 15 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Ran from Jun 2018 to primary completion in Dec 2022, 54 months.
Results were first posted in Jan 2024, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gantenerumab